FLX 787

Drug Profile

FLX 787

Alternative Names: FLX-788; FLX-797; FLX-798; FLX787; TRP activators - Flex Pharma; TRPA1 activators - Flex Pharma; TRPV1 activators - Flex Pharma

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Flex Pharma
  • Class
  • Mechanism of Action TRPA1 protein stimulants; TRPV cation channel agonists; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Multiple sclerosis
  • Phase I Motor neuron disease
  • Preclinical Neuromuscular disorders

Most Recent Events

  • 08 Mar 2017 Flex Pharma plans phase II trials for Amyotrophic lateral sclerosis and peripheral neuropathies such as Charcot-Marie-Tooth disease in USA (PO, disintegrating tablet)
  • 02 Nov 2016 Flex Pharma announces intention to submit IND to US FDA for phase II trial for Nocturnal leg cramps
  • 02 Nov 2016 Flex Pharma plans a phase II trial for Nocturnal leg cramps in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top